Occam Places Eva Jack as COO of Hotspot
HotSpot is a private biotech and an investment of Atlas Venture. The company recently raised $100M in a Series C financing and has a platform addressing a number of major disease states including oncology and rare diseases.
In late 2020, Occam recruited Eva Jack, previously CBO of Mersana Therapeutics, to be the COO in a role that would also encompass Business Development.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.